Search Videos by Topic or Participant
Browse by Series:

Multiple PD-1/PD-L1 Agents in Lung Cancer

Panelists: D. Ross Camidge, MD, PhD, University of Colorado;Ramaswamy Govindan, MD, Siteman; Roy S. Herbst, MD, PhD, Yale; Corey J. Langer, MD, Penn
Published: Sunday, Nov 23, 2014
For High-Definition, Click
The PD-1 inhibitor pembrolizumab has demonstrated promise in patients with non-small cell lung cancer (NSCLC), explains Alice T. Shaw, MD, PhD. Results presented at ASCO 2014 demonstrated an overall response rate by RECIST of 26%. The disease control rate, defined as complete response, partial response, and stable disease, was 64%.

The PD-1 inhibitors have demonstrated a great deal of promise in melanoma, with approvals gained for both the pembrolizumab and nivolumab. Both drugs are being explored in phase III studies, with promising results already announced. In addition to the efficacy seen with these agents, their side effects seem to be tolerable, notes Corey J. Langer, MD.

In addition to PD-1 inhibitors, PD-L1 blocking agents are also showing promise. The PD-L1 inhibitor MPDL3280A demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, notes D. Ross Camidge, MD, PhD.

Patients treated with these agents are commonly tested for PD-L1 positivity. However, responses are indicated, whether positive or negative; with a higher response seen in positive patients. If a patient is positive, a PD-1/PD-L1 agent could be used in the frontline setting, Camidge notes. However, if negative, a PD-1 inhibitor can be utilized in a later setting. 
Slider Left
Slider Right
For High-Definition, Click
The PD-1 inhibitor pembrolizumab has demonstrated promise in patients with non-small cell lung cancer (NSCLC), explains Alice T. Shaw, MD, PhD. Results presented at ASCO 2014 demonstrated an overall response rate by RECIST of 26%. The disease control rate, defined as complete response, partial response, and stable disease, was 64%.

The PD-1 inhibitors have demonstrated a great deal of promise in melanoma, with approvals gained for both the pembrolizumab and nivolumab. Both drugs are being explored in phase III studies, with promising results already announced. In addition to the efficacy seen with these agents, their side effects seem to be tolerable, notes Corey J. Langer, MD.

In addition to PD-1 inhibitors, PD-L1 blocking agents are also showing promise. The PD-L1 inhibitor MPDL3280A demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, notes D. Ross Camidge, MD, PhD.

Patients treated with these agents are commonly tested for PD-L1 positivity. However, responses are indicated, whether positive or negative; with a higher response seen in positive patients. If a patient is positive, a PD-1/PD-L1 agent could be used in the frontline setting, Camidge notes. However, if negative, a PD-1 inhibitor can be utilized in a later setting. 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x